# Clinical Trial to to Compare of the Efficacy and Safety of Lipilou® 20 mg and Lipilou® 10 mg

Study · id `cardio:ct-nct04511000` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04511000](<https://clinicaltrials.gov/study/NCT04511000>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04511000

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 250 participants.

## Technical summary

Registry record NCT04511000. Randomized; no masking; primary purpose treatment. Start 2017-10-11 (actual); primary completion 2019-05-20 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 250 participants (enrolled count; ClinicalTrials.gov record NCT04511000, source copy `cardio:ctgov-nct04511000-2020-08-12`, retrieved 2026-10-31)
- Started: 2017-10-11 (actual) (ClinicalTrials.gov record NCT04511000, source copy `cardio:ctgov-nct04511000-2020-08-12`, retrieved 2026-10-31)
- Primary completion: 2019-05-20 (actual) (ClinicalTrials.gov record NCT04511000, source copy `cardio:ctgov-nct04511000-2020-08-12`, retrieved 2026-10-31)
- Completion: 2019-05-20 (actual) (ClinicalTrials.gov record NCT04511000, source copy `cardio:ctgov-nct04511000-2020-08-12`, retrieved 2026-10-31)
- Countries: South Korea (ClinicalTrials.gov record NCT04511000, source copy `cardio:ctgov-nct04511000-2020-08-12`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04511000-2020-08-12`, retrieved 2026-10-31)

## The registry's words

- Brief title: Clinical Trial to to Compare of the Efficacy and Safety of Lipilou® 20 mg and Lipilou® 10 mg
- Condition: Hypercholesterolemia
- Intervention (Drug): Lipilou®(generic atorvastatin drug) 20 mg
- Intervention (Drug): Lipilou®(generic atorvastatin drug) 10 mg
- Lead sponsor: Chong Kun Dang Pharmaceutical
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry lists this organization as the lead sponsor: Chong Kun Dang Pharmaceutical (`cardio:org-chong-kun-dang-pharmaceutical`)

## Provenance

Content hash: ce02a2bcfa355a5fb44b234cb57690ef8652495469f16e887247ce785c4cc6d0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
